Gland Pharma reported a stellar fourth quarter for FY26, achieving consolidated revenue of INR 17,428 million, a 22% year-on-year increase. The company’s adjusted EBITDA stood at INR 5,244 million with a strong 30% margin. Growth was driven by robust performance in the CDMO segment, new product launches like Dalbavancin, and operational efficiencies. The management remains confident in achieving a 15% CAGR over the next four years, supported by a healthy pipeline and capacity expansion.
Quarterly Financial Performance
Gland Pharma delivered a record-breaking performance in Q4 FY26. The company reported a 22% year-on-year revenue growth, totaling INR 17,428 million. Profitability metrics also saw significant improvement, with an adjusted EBITDA of INR 5,244 million (30% margin) and an adjusted profit after tax of INR 3,667 million (21% margin). For the full fiscal year, consolidated revenue reached INR 64,307 million, reflecting a 14.5% growth.
Strategic Growth Drivers
The company’s growth is anchored by its CDMO business, which now represents 46% of total revenue. During the year, the CDMO segment grew by 28%. Key successes included the launch of 31 new products in the U.S. market, notably Dalbavancin, which has seen strong demand. Management highlighted that eight GLP-1 contracts have already been signed, with further contracts expected, reinforcing the CDMO sector as a primary pillar of the firm’s long-term strategy.
Cenexi Turnaround and Operational Updates
The Cenexi business has shown a significant turnaround, becoming EBITDA positive and contributing to group stability. With revenues of EUR 45 million for the quarter, Cenexi is poised for growth through higher capacity utilization and contract renegotiations. Strategic investments are underway, including an INR 2,000 crore capital expenditure plan over the next five years to support capacity expansions in India and high-value CDMO projects, including microsphere manufacturing and nanotechnology.
Future Outlook
Looking ahead, Gland Pharma projects a 15% CAGR on a consolidated basis for the next four years. While maintaining a steady 12% to 13% growth forecast for FY27 at constant currency, the company anticipates a potential step-up in growth by FY29 driven by the launch of complex products currently in the pipeline. The focus remains on cost optimization, yield improvements, and leveraging high-end product launches to sustain healthy margins.
Source: BSE
